

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Complete if Known

Application Number	National Phase Entry of PCT/EP03/01809
Filing Date	Herewith <b>10/505482</b>
First Named Inventor	STREBHARDT et al
Group Art Unit	
Examiner Name	

 Sheet **1** of **2** Attorney Docket Number **2923-656**
**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
<b>SW</b>	<b>1.</b>	<b>6,183,961</b>	<b>B1</b>	<b>Harold S. Bernstein et al</b>	<b>2/6/01</b>

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			

Examiner  
Signature**Louis Dollenberger**Date  
Considered**4/21/05**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete Known	
				Application Number	National Phase Entry of PCT/EP03/01809
				Filing Date	Herewith <b>10/505482</b>
				First Named Inventor	STREBHARDT et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2923-656
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
SW	2.	Wolf et al., "Inhibition of tumor cell proliferation in vitro by antisense oligonucleotides directed against the serine-threonine-kinase PLK", PATHOLOGY RESEARCH AND PRACTICE, vol. 196, no. 6, 7 June 2000, pg. 352			
SW	3.	Wolf et al., "Antitumor activity of an antisense oligodeoxynucleotide targeted against human polo-like kinase PLK", INT. J. OF MOLECULAR MEDICINE, vol. 6, no. supp., - 2000 page s80.			
SW	4.	Yuan et al., "Polo-like kinase, a novel marker for cellular proliferation", AM. J. Pathol., vol. 150, no. 4, April 1997, pgs. 1165-1172.			
SW	5.	Thompson, "Applications of antisense and siRNAs during preclinical drug development", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, vol. 7, no. 17, 1 September 2002, pgs. 912-917.			
SW	6.	Tuschl, "RNA interference and small interfering RNAs", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, vol. 2, no. 4, April 2001, pgs. 239-245.			
SW	7.	Spaenkuch-Schmitt et al., "Inhibition of polo-like kinase 1 by antisense oligonucleotides and RNA interference", EUROPEAN J. OF CANCER, vol. 38, no. supp7, 22 November 2002, page s144.			
Examiner Signature	Louis Wollenberger			Date Considered	11/21/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.